A recent study suggests that apitegromab, a monoclonal antibody, may help preserve lean body mass when combined with weight-loss injections known as GLP-1 receptor agonists, like tirzepatide. These injections effectively reduce fat but also lead to significant lean muscle loss, which can adversely affect strength and increase the risk of type 2 diabetes. Dr. Brendan Gabriel from the University of Aberdeen notes that skeletal muscle plays a critical role in preventing diabetes and cardiovascular disease. In the study published in Nature Medicine, 102 participants were divided into two groups: one received apitegromab with tirzepatide, while the other received a placebo. Results showed that those on apitegromab lost only 1.6kg of lean mass compared to 3.5kg in the placebo group. Despite promising findings, researchers caution that the study's small size and short duration necessitate larger, longer trials to validate the drug's efficacy and safety. Dr. Marie Spreckley from the University of Cambridge highlighted the need for more research to determine if preserving lean mass can lead to improved long-term health outcomes.